*本文所涉及专业部分,仅供医学专业人士阅读参考
导语
2021年1月7日,中国上海专注于内分泌相关疾病治疗的维昇药业(VISEN Pharmaceuticals)宣布其向中国国家药品监督管理局(NMPA)递交的注射用TransCon CNP(TransCon C-型利钠肽)用于软骨发育不全(ACH)患者的II期新药临床试验申请已经获得批准,即将在中国开展ACcomplisH China临床试验,实现了与ACcomplisH [ 一项正在由Ascendis Pharma开展的TransCon C-型利钠肽(CNP) II期全球临床试验 ] 全球同步。
软骨发育不全患者
面临多重困境亟待解决
TransCon CNP II期临床研究全球同步,
加速研发进程
维昇药业致力于“患者为先”,
以中国临床数据推动全球研发进程
前瞻性声明
https://www.ncbi.nlm.nih.gov/books/NBK1152/
Pauli RM. Orphanet J Rare Dis. 2019;14(1):1-49
Waller DK, Correa A, Vo TM, Wang Y, Hobbs C, Langlois PH, et al. The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US. Am J Med Genet A 2008;146A: 2385–9
Tachibana K, Suwa S, Nishiyama S, Matsuda I. Study on height in patients with achondroplasia by national survey. Shounika Sinryou 1997;60: 1363–9
Vibeke Miller Breinholt, et al. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3–Related Skeletal Dysplasias. J Pharmacol Exp Ther. 2019;370(3):459-471
TransCon CNP: A Once Weekly Novel C type Natriuretic Peptide Therapy in Children with Achondroplasia, Sho Ota, PharmD Ascendis Pharma, A/S; ISDS CONFERENCE SEPTEMBER 2019, OSLO
ENDO 2017 PR
TransCon CNP: Preliminary Phase 1 Data November 28, 2018
联系客服